Orbimed Advisors LLC Adc Therapeutics Sa Transaction History
Orbimed Advisors LLC
- $4.15 Billion
- Q2 2024
A detailed history of Orbimed Advisors LLC transactions in Adc Therapeutics Sa stock. As of the latest transaction made, Orbimed Advisors LLC holds 4,316,824 shares of ADCT stock, worth $13.4 Million. This represents 0.33% of its overall portfolio holdings.
Number of Shares
4,316,824Holding current value
$13.4 Million% of portfolio
0.33%Shares
1 transactions
Others Institutions Holding ADCT
# of Institutions
79Shares Held
52.9MCall Options Held
300KPut Options Held
59.3K-
Redmile Group, LLC San Francisco, CA15.3MShares$47.3 Million3.15% of portfolio
-
Prosight Management, LP Dallas, TX9.57MShares$29.7 Million9.45% of portfolio
-
Black Rock Inc. New York, NY3.55MShares$11 Million0.0% of portfolio
-
Morgan Stanley New York, NY2.97MShares$9.19 Million0.0% of portfolio
-
Silverarc Capital Management, LLC1.77MShares$5.48 Million1.59% of portfolio
About ADC Therapeutics SA
- Ticker ADCT
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,645,296
- Market Cap $241M
- Description
- ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...